Company intelligence / Profile preview

HYpharm

Ownership: Private
Development stage: Preclinical

Overview

HYpharm’s lead candidate, HY‑133—a recombinant bacteriophage endolysin formulated as a nasal hydrogel—is in Phase 1 clinical development for the prevention/treatment of staphylococcal colonization/infection. The company collaborates with academic partners and the German Center for Infection Research to advance this novel approach against multi-drug resistant bacteria. No published clinical results yet; preclinical data support efficacy against various resistant staph strains.

Therapeutic areas: Infectious Diseases
Modalities: Bacteriophage-derived proteins (recombinant endolysins)
Industry: Biotech

Drug pipeline

2 assets

HY-133

1 more asset in the full pipeline.

Partnerships

German Center for Infection Research (DZIF)university collaborationsBEAM AllianceDNAMR networks

Beyond the preview

Go deeper on HYpharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HYpharm.